Pharmaceuticals
All research in Pharmaceuticals — 7 reports.
AstraZeneca is an innovative-drug giant built around oncology and rare disease, monetizing through R&D and global commercialization. 2025 revenue reached 58.739 billion USD, with the growth engine shifting toward oncology (+20% year over year) and rare disease (+19%) to offset pressure on legacy CVRM drugs, leaving its multi-platform structure more balanced than single-engine peers. Rating Hold: at the current 178.75 USD the stock still trades at a premium to conservative intrinsic value with no meaningful margin of safety, a high-quality name that has entered a delivery-pressure phase.
Novartis is one of the world's top ten innovative pharmaceutical companies, headquartered in Basel, Switzerland, and has repositioned itself as a pure-play innovative medicines company after spinning off Sandoz in October 2023. Its portfolio spans cardiovascular, oncology, immunology, neuroscience, and rare diseases, supported by 2025 revenue of about $56.6 billion, a 30% operating margin, roughly $15 billion in free cash flow, and 28 consecutive years of dividend increases, while Entresto's U.S. generic entry in Q4 2025 remains the key near-term challenge. Research rating Hold: a high-quality defensive compounder with a deep moat, but the current price already reflects neutral expectations and leaves limited margin of safety.
LongBio Pharma is a China 18A innovative-drug IPO candidate whose core anti-IgE antibody LP-003 is nearing BLA submission. As of 2026-06-03, it had not yet started trading, and the HK$96.06 offer price already reflected substantial success expectations while standing well above a conservative intrinsic value of HK$67.4. Rating Watch: a zero-revenue, zero-profit biotech with value highly concentrated in LP-003 and an ideal buy price at or below HK$54.
A global platform of generics and mature branded drugs with steady cash flow but a thin moat and middling asset quality. At roughly $16.26 the stock sits in the lower half of fair value, leaving an insufficient margin of safety. Rating Watch: a fairly priced cash-flow business that lacks the durable advantages to compound, with an ideal entry of $11-13.5.
Moderna is an mRNA-platform biopharmaceutical company that began with COVID vaccines and still has adequate cash, but has entered a cash-burning transition period that depends on new products taking over. Its value depends heavily on a small number of approvals and Phase 3 oncology outcomes, while the margin of safety is insufficient. Report rating Watch: a technically strong but highly uncertain platform asset that should stay on the watchlist rather than in a conservative core portfolio.
The tirzepatide platform has put Lilly at the top of the metabolic disease arena, but the $732 share price has already paid in advance for the next-generation pipeline and capacity expansion; a neutral DCF intrinsic value of only $560-680 leaves an insufficient margin of safety, making it better to wait for a pullback. Rating Watch: a great business whose current price gives long-term owners too little room for error.
A high-quality pharma business: ROIC sits at a lofty 39-88%, with 55% share in once-weekly injectable GLP-1. But facing Lilly's oral GLP-1 launch, U.S. pricing policy, and semaglutide losing exclusivity in some international markets, the stock trades at 20-23x on an Owner Earnings basis. Rating Watch: the cheapness of a static 12.5x PE is an illusion, and today's price offers no clear margin of safety.